tiprankstipranks
Trending News
More News >

Mediwound’s EscharEx Shows Promising Results in Phase 3 Trial

Story Highlights
Mediwound’s EscharEx Shows Promising Results in Phase 3 Trial

Don’t Miss TipRanks’ Half-Year Sale

Clal Biotech ( (IL:CBI) ) has issued an update.

Mediwound, under Clal Biotechnology Industries Ltd., announced the approval of a Phase 3 clinical trial for its EscharEx treatment, showing a significant improvement in healing time for chronic wounds. The trial demonstrated a 14% improvement over existing treatments and a 40-day reduction in wound closure time, positioning EscharEx as a potential new standard in chronic wound care.

More about Clal Biotech

Mediwound, a leader in innovative treatment technologies, focuses on the development and commercialization of products for wound care. The company offers products such as NexoBrid for severe burns and EscharEx for chronic wounds, and is dedicated to improving patient outcomes through innovative solutions.

YTD Price Performance: -4.18%

Average Trading Volume: 113,830

Current Market Cap: ILS54.74M

Find detailed analytics on CBI stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1